 All patients andor their families will be alerted about the need to monitor for the medication side effects including any neuropsychiatric symptoms. Since the beginning of the treatment and during each in-hospital visit or follow up phone calls, patients will be asked about changes in their behavior or thoughts. Patients will be instructed to stop taking the medication or placebo and contact their healthcare provider and the research coordinator immediately if they have or if their families observe depressed mood, agitation, hostility or changes in behavior, that are not typical for the patient, or if the patient has suicidal ideation or suicidal behavior. These patients will be unblinded, withdrawn from the study, and recorded as cases with serious adverse events SAE. They will be followed up for at least 28 days after the stop of the treatments for monitoring any more complications. 